Empiric Antibiotic Recommendations for Delayed or Dehiscing Abdominal Infections

Treatment Algorithm Based on Infection Severity

For non-critically ill patients with healthcare-associated delayed or dehiscing abdominal infections, the Infectious Diseases Society of America recommends piperacillin-tazobactam 3.375g IV every 6 hours as the first-line empiric therapy due to its broad spectrum coverage against both aerobic and anaerobic pathogens 1
For non-critically ill patients with high risk for ESBL-producing organisms, alternative options include meropenem 1g IV every 8 hours, doripenem 500mg IV every 8 hours, imipenem/cilastatin 1g IV every 8 hours, or cefepime 2g every 8-12 hours plus metronidazole 500mg every 6 hours 1, 2

For patients with beta-lactam allergies, the Infectious Diseases Society of America recommends ciprofloxacin 400mg IV every 12 hours plus metronidazole 500mg IV every 6 hours or tigecycline 100mg IV initial dose, then 50mg IV every 12 hours 1, 2
For patients at risk for enterococcal infections, adding ampicillin 2g IV every 6 hours is recommended if not already using piperacillin-tazobactam or imipenem-cilastatin, which cover ampicillin-susceptible enterococci 1, 2

The Infectious Diseases Society of America recommends limiting antimicrobial therapy to 4-7 days unless source control is difficult to achieve, as longer durations have not been associated with improved outcomes 4
Therapy should be tailored when culture and susceptibility reports become available, according to the Infectious Diseases Society of America 4, 5

The Society of Critical Care Medicine emphasizes that source control through surgical intervention or drainage remains the cornerstone of treatment for intra-abdominal infections 1
Initial inadequate antimicrobial therapy is associated with increased morbidity, mortality, and length of hospital stay, according to the European Society of Clinical Microbiology and Infectious Diseases 6
Local resistance patterns should guide empiric therapy choices, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 7
The Infectious Diseases Society of America advises avoiding ampicillin-sulbactam due to high rates of resistance among community-acquired E. coli, and avoiding cefotetan and clindamycin due to increasing resistance among Bacteroides fragilis group 5

Delaying appropriate antimicrobial therapy increases risk of death, necessity for reoperation, and prolonged hospitalization, according to the European Society of Clinical Microbiology and Infectious Diseases 6
Using overly broad spectrum antibiotics for mild-to-moderate community-acquired infections may increase toxicity and facilitate acquisition of resistant organisms, as warned by the Infectious Diseases Society of America 5
Failing to adjust therapy based on culture results once available is a common pitfall, according to the Infectious Diseases Society of America 5
Continuing antibiotics beyond 7 days when adequate source control has been achieved is not recommended by the Infectious Diseases Society of America 4